CN109745868B - 一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 - Google Patents
一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 Download PDFInfo
- Publication number
- CN109745868B CN109745868B CN201910071276.1A CN201910071276A CN109745868B CN 109745868 B CN109745868 B CN 109745868B CN 201910071276 A CN201910071276 A CN 201910071276A CN 109745868 B CN109745868 B CN 109745868B
- Authority
- CN
- China
- Prior art keywords
- hollow fiber
- fiber membrane
- casting solution
- polyether sulfone
- antibacterial hollow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 119
- 239000012510 hollow fiber Substances 0.000 title claims abstract description 106
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 208000037157 Azotemia Diseases 0.000 title claims abstract description 24
- 208000009852 uremia Diseases 0.000 title claims abstract description 24
- 239000004695 Polyether sulfone Substances 0.000 claims abstract description 130
- 229920006393 polyether sulfone Polymers 0.000 claims abstract description 130
- 238000005266 casting Methods 0.000 claims abstract description 100
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 51
- 239000010703 silicon Substances 0.000 claims abstract description 51
- 239000004332 silver Substances 0.000 claims abstract description 36
- 229910052709 silver Inorganic materials 0.000 claims abstract description 36
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000009987 spinning Methods 0.000 claims abstract description 15
- 230000004048 modification Effects 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 131
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 80
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 48
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 30
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 30
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 29
- 239000000725 suspension Substances 0.000 claims description 25
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 24
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 19
- 230000001112 coagulating effect Effects 0.000 claims description 18
- 238000005507 spraying Methods 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000006277 sulfonation reaction Methods 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000012266 salt solution Substances 0.000 claims description 6
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims description 6
- 150000008282 halocarbons Chemical class 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000004088 foaming agent Substances 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 238000002166 wet spinning Methods 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000010410 layer Substances 0.000 abstract description 103
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 19
- -1 silver ions Chemical class 0.000 abstract description 18
- 239000002441 uremic toxin Substances 0.000 abstract description 18
- 238000001631 haemodialysis Methods 0.000 abstract description 11
- 230000000322 hemodialysis Effects 0.000 abstract description 11
- 239000003053 toxin Substances 0.000 abstract description 5
- 231100000765 toxin Toxicity 0.000 abstract description 5
- 239000002344 surface layer Substances 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 238000003756 stirring Methods 0.000 description 22
- 239000012153 distilled water Substances 0.000 description 21
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 13
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 13
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 13
- 230000007935 neutral effect Effects 0.000 description 13
- 238000002791 soaking Methods 0.000 description 13
- 238000000967 suction filtration Methods 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 12
- 238000004140 cleaning Methods 0.000 description 12
- 238000004108 freeze drying Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 11
- 238000004176 ammonification Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 229930003779 Vitamin B12 Natural products 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000011715 vitamin B12 Substances 0.000 description 7
- 235000019163 vitamin B12 Nutrition 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001951 hemoperfusion Effects 0.000 description 6
- WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 229940045136 urea Drugs 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 230000008081 blood perfusion Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- RCICMVVXMOWCPC-UHFFFAOYSA-N 4-methylphenol;sulfuric acid Chemical compound OS(O)(=O)=O.CC1=CC=C(O)C=C1 RCICMVVXMOWCPC-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 125000003916 ethylene diamine group Chemical group 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical compound OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000002149 hierarchical pore Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- FVIRGMIYFJWRGC-UHFFFAOYSA-N sulfurobromidic acid Chemical compound OS(Br)(=O)=O FVIRGMIYFJWRGC-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Landscapes
- Separation Using Semi-Permeable Membranes (AREA)
- Artificial Filaments (AREA)
Abstract
Description
尿素(%) | 肌酐(%) | 维生素B12(%) | 硫酸对甲酚(%) | |
实施例1 | 92.3 | 83.2 | 43.1 | 70.3 |
实施例2 | 91.9 | 84.1 | 42.5 | 74.0 |
实施例3 | 93.1 | 88.2 | 40.5 | 74.9 |
实施例4 | 92.5 | 86.2 | 40.4 | 79.4 |
实施例5 | 91.0 | 81.4 | 41.6 | 81.4 |
实施例6 | 92.0 | 81.4 | 42.8 | 76.3 |
实施例7 | 92.5 | 84.1 | 42.5 | 75.2 |
实施例8 | 91.7 | 84.2 | 41.5 | 72.4 |
实施例9 | 90.5 | 85.0 | 40.8 | 77.4 |
对比例1 | 86.7 | 77.9 | 38.9 | 30.7 |
对比例2 | 87.9 | 81.6 | 40.7 | 50.1 |
对比例3 | 73.1 | 67.6 | 38.6 | 42.9 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910071276.1A CN109745868B (zh) | 2019-01-25 | 2019-01-25 | 一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910071276.1A CN109745868B (zh) | 2019-01-25 | 2019-01-25 | 一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109745868A CN109745868A (zh) | 2019-05-14 |
CN109745868B true CN109745868B (zh) | 2021-05-25 |
Family
ID=66406202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910071276.1A Active CN109745868B (zh) | 2019-01-25 | 2019-01-25 | 一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109745868B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109794172B (zh) * | 2019-01-25 | 2021-05-14 | 广东省医疗器械研究所 | 一种用于血液净化的抗菌中空纤维膜的制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103285740B (zh) * | 2012-02-23 | 2015-04-22 | 中国科学院宁波材料技术与工程研究所 | 一种抗菌双层中空纤维膜的制备方法 |
KR101361704B1 (ko) * | 2012-03-08 | 2014-02-11 | 한국과학기술연구원 | 수처리용 분리막 및 그 제조 방법 |
CN103394334B (zh) * | 2013-07-11 | 2015-07-08 | 东华大学 | 一种高比表面积胺化纳米纤维膜的制备方法 |
JP2017514957A (ja) * | 2014-05-01 | 2017-06-08 | サビック グローバル テクノロジーズ ベスローテン フェンノートシャップ | ポリ(フェニレンエーテル)および両親媒性ポリマを含む支持体を有する複合膜、製造方法、およびその分離モジュール |
CN105617876A (zh) * | 2014-11-06 | 2016-06-01 | 中国科学院宁波材料技术与工程研究所 | 一种缓释型抗菌双层中空纤维膜及其制备方法 |
CN106582304B (zh) * | 2016-12-30 | 2019-09-03 | 浙江工业大学 | 一种荷电镶嵌膜的制备方法 |
CN107955171B (zh) * | 2017-12-26 | 2021-01-05 | 健帆生物科技集团股份有限公司 | 一种蛋白结合毒素印迹硅胶吸附剂的制备方法及吸附装置 |
-
2019
- 2019-01-25 CN CN201910071276.1A patent/CN109745868B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN109745868A (zh) | 2019-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101703893B (zh) | 空心纤维超滤复合膜及其制备方法和应用 | |
JP2019504767A (ja) | 高選択性促進輸送膜およびオレフィン/パラフィン分離のためのその使用 | |
CN109675134B (zh) | 一种血液透析器的抗凝改性方法及其应用 | |
CN101804307B (zh) | 抗凝血复合超滤膜及其制备方法 | |
Liu et al. | Alginate/HSA double-sided functional PVDF multifunctional composite membrane for bilirubin removal | |
CN109745868B (zh) | 一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 | |
CN106310970B (zh) | 一种用于血液透析的改性聚偏氟乙烯中空纤维膜 | |
JPWO2002034374A1 (ja) | 親水化膜およびその処理方法 | |
JP2012005827A (ja) | ハイモビリティーグループタンパク吸着担体 | |
CN109331750B (zh) | 一种类肝素凝胶微球及其制备方法和用途 | |
CN109794172B (zh) | 一种用于血液净化的抗菌中空纤维膜的制备方法 | |
CN105709613A (zh) | 一种有效去除中等生物分子的纳米纤维复合膜及其制备方法和应用 | |
CN102258946B (zh) | 一种低密度脂蛋白亲和吸附血液透析膜材料的制备方法 | |
CN107413205A (zh) | 透析废液净化用中空纤维膜及其加工方法 | |
CN103230781A (zh) | 一种用于血液净化法去除内毒素的肝素-苯丙氨酸吸附材料 | |
CN116966756A (zh) | 一种清除促炎性细胞因子的血液净化膜及其制备方法 | |
CN109692372A (zh) | 一种五层血液灌流器及血液灌流方法 | |
CN107381970B (zh) | 一种透析废液净化装置 | |
CN114225919B (zh) | 一种内毒素吸附剂及其制备方法与应用 | |
CN113509919B (zh) | 一种可用于清除脓毒症患者血液中内毒素和炎症因子的吸附剂及其制备方法 | |
CN109174022B (zh) | 一种血液净化用吸附材料的固定化方法 | |
CN103252177A (zh) | 一种糖基/磺化改性亲和聚合物中空纤维分离膜、其制备方法及用途 | |
CN203139198U (zh) | 简易血液净化器 | |
CN207537303U (zh) | 一种透析废液净化装置 | |
JP2011000145A (ja) | 中空糸状血液浄化膜及び中空糸状血液浄化膜の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: No. 1307, Guangzhou Avenue middle, Tianhe District, Guangzhou, Guangdong 510500 Patentee after: Institute of health medicine, Guangdong Academy of Sciences Country or region after: China Address before: No. 1307, Guangzhou Avenue middle, Tianhe District, Guangzhou, Guangdong 510500 Patentee before: GUANGDONG INSTITUTE OF MEDICAL INSTRUMENTS Country or region before: China |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240206 Address after: No.10, shiliugang Road, Haizhu District, Guangzhou City, Guangdong Province 510000 Patentee after: Institute of biological and medical engineering, Guangdong Academy of Sciences Country or region after: China Address before: No. 1307, Guangzhou Avenue middle, Tianhe District, Guangzhou, Guangdong 510500 Patentee before: Institute of health medicine, Guangdong Academy of Sciences Country or region before: China |
|
TR01 | Transfer of patent right |